Key Highlights
- Celularity sold an exclusive license to NexGel for $13.3 million in total consideration.
- Consideration included $4.8 million in cash at closing and a $5.0 million convertible note.
- Up to $20.0 million in milestone payments could follow.
- Second-quarter Revenue was $5.4 million, with Net Income of $0.7 million.
Celularity Inc. (NASDAQ:CELU) has spent much of 2026 restructuring its balance sheet, and one transaction from April continues to shape its financial picture: an exclusive license sold to NexGel (NASDAQ:NXGL). The deal brought in near-term cash, transferred certain liabilities and created the possibility of up to $20.0 million in future milestone payments.
Latest Company Context
According to Celularity's Form 10-Q for the quarter ended June 30, 2026, accepted by the SEC on October 20, 2026, the company sold an exclusive, transferable and sublicensable license to NexGel for $13.3 million. Consideration included $4.8 million in cash at closing, a further $0.6 million in cash during the second quarter contingent on filing its 2025 annual report, NexGel's assumption of $2.9 million in employee sales commissions, and a $5.0 million, 18-month convertible note issued by NexGel.
Up to $20.0 million in milestone payments could follow. The same filing showed second-quarter total revenue of $5.4 million versus $5.7 million a year earlier, with product sales rising to $4.1 million from $2.4 million. Net income was $0.7 million, aided by a $6.7 million settlement gain, compared with a $24.5 million net loss a year earlier.
Key Business and index Drivers
The NexGel deal illustrates a broader shift in how Celularity is monetizing its assets. License, Royalty and other revenue fell to $0.7 million in the second quarter from $2.1 million, and services revenue declined to $0.7 million from $1.3 million, leaving product sales as the largest line. Converting a license into cash, a note and contingent milestones may provide liquidity, but it also means some future Economics depend on NexGel's execution; the value of the convertible note, for instance, is tied to NexGel's own performance.
Liquidity remains tight. Cash and equivalents were $586 thousand at June 30, 2026, alongside $9.8 million of restricted cash, and current liabilities of $59.7 million far exceeded current Assets of $6.4 million. The filing states there is substantial doubt about the company's ability to continue as a going concern. An initial Recapitalization closing on September 24, 2026 generated $8.8 million of net cash.
What Investors Should Watch
The third-quarter 10-Q, covering the period ended September 30, 2026, is the nearest disclosure point and may show how much NexGel consideration has been received and how the September recapitalization changed the cash position. The June-quarter filing noted that any Nasdaq extension for periodic-filing compliance ran no later than November 16, 2026, so investors may watch for exchange correspondence. Further out, the potential $15.0 million second Tranche of the recapitalization, the NexGel note's Maturity roughly 18 months after the April 2026 deal, and any disclosure of milestone achievement could be meaningful. Product sales trends for biomaterials, including brands such as Biovance and Interfyl listed among the company's trademarks, could also indicate whether Operating Revenue can support the business with less reliance on one-time gains.
License Trades Optionality for Liquidity
The NexGel license is a clear example of Celularity trading future optionality for present liquidity. It delivered cash and Liability relief at a difficult moment, while leaving up to $20.0 million in milestones and a convertible note as contingent upside. Whether that structure ultimately proves valuable may depend on NexGel's progress as much as on Celularity's own. For now, the company's going-concern disclosure and filing obligations keep near-term execution in focus, and upcoming reports could clarify how far the turnaround has progressed.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...